GSK plc
GLAXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $31 | $30 | $29 | $34 |
| % Growth | 3.5% | 3.4% | -14% | – |
| Cost of Goods Sold | $9 | $9 | $10 | $12 |
| Gross Profit | $22 | $22 | $20 | $23 |
| % Margin | 71.2% | 71.8% | 67.4% | 66% |
| R&D Expenses | $6 | $6 | $5 | $5 |
| G&A Expenses | $11 | $9 | $8 | $11 |
| SG&A Expenses | $11 | $9 | $8 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | -$1 | $0 | $0 |
| Operating Expenses | $18 | $15 | $13 | $16 |
| Operating Income | $4 | $7 | $6 | $6 |
| % Margin | 12.8% | 22.2% | 21.9% | 18.2% |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$2 |
| Pre-Tax Income | $3 | $6 | $6 | $4 |
| Tax Expense | $1 | $1 | $1 | $0 |
| Net Income | $3 | $5 | $15 | $4 |
| % Margin | 8.2% | 16.2% | 51% | 12.9% |
| EPS | 0.63 | 1.2 | 3.71 | 1.37 |
| % Growth | -47.5% | -67.7% | 170.8% | – |
| EPS Diluted | 0.62 | 1.2 | 3.66 | 1.35 |
| Weighted Avg Shares Out | 4 | 4 | 4 | 3 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $3 | $2 | $2 | $2 |
| EBITDA | $7 | $9 | $9 | $6 |
| % Margin | 21.3% | 29.9% | 29.3% | 19% |